Journal
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
Volume 39, Issue -, Pages 6-13Publisher
WILEY
DOI: 10.1111/ijlh.12659
Keywords
antigen-presenting cells; B cells; factor VIII; hemophilia A; immunity; inhibitors; T cells; tolerance
Categories
Funding
- Canadian Institutes of Health Research
Ask authors/readers for more resources
In the treatment of hemophilia A, the 20%-30% risk of developing of anti-factor VIII (FVIII) antibodies, or inhibitors, is the dominant concern among healthcare providers. Immune tolerance induction remains the only effective method of eradicating inhibitors in approximately 75% of patients, but is accompanied by significant emotional and economical burden. While certain risk factors, such as the type of FVIII mutation, offer some insight, there remains no strategy to confidently predict the development of an inhibitor. Moreover, even if such a predictive tool existed, there is currently no proven protocol for tolerance induction of a previously untreated patient. In recent years, the growing body of knowledge concerning the fundamental immunology of inhibitors has shed light on potential therapeutic interventions. In this review, we highlight these new findings and their influences on translational medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available